Table 3.

Correlation between sKIT status, treatment group, and TTP

(A) C2;D28
All patients* (n = 194)
sKITSunitinib, n (%)Placebo, n (%)
sKIT ↑37 (24.2)38 (92.7)
sKIT ↓116 (75.8)3 (7.3)
sKIT ↑ (n = 75)sKIT ↓ (n = 119)
TTP (mo)Sunitinib, n (%)Placebo, n (%)TTP (mo)Sunitinib, n (%)Placebo, n (%)
<622 (59.5)25 (65.8)<639 (33.6)3 (100)
≥615 (40.5)13 (34.2)≥677 (66.4)0 (0)
(B) C3;D1
All patients* (n = 168)
sKITSunitinib, n (%)Placebo, n (%)
sKIT ↑22 (17.5)37 (88.1)
sKIT ↓104 (82.5)5 (11.9)
sKIT ↑ (n = 59)sKIT ↓ (n = 109)
TTP (mo)Sunitinib, n (%)Placebo, n (%)TTP (mo)Sunitinib, n (%)Placebo, n (%)
<613 (59.1)25 (67.6)<627 (26.0)4 (80.0)
≥69 (40.9)12 (32.4)≥677 (74.0)1 (20.0)

NOTE: ↑, increase relative to baseline; ↓, decrease relative to baseline.

  • *With matched pairs of baseline and on-study plasma samples for sKIT at the indicated time point.